Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene

European Journal of Clinical Pharmacology

Volumn 60, Issue 5, 2004, Pages 369-372

  Hedenmalm, Karin ^a   Lindh, Jonatan D ^b   Säwe, Juliette ^c   Rane, Anders ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Swedish Council on Technology Assessment in Health Care   (Sweden)

Author keywords

Cytochrome P450; Tramadol; Warfarin

Indexed keywords

AMILORIDE; BUDESONIDE; CALCIUM CARBONATE; CAPTOPRIL; CYCLIZINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; DIGOXIN; FUROSEMIDE; GLIPIZIDE; GLYCERYL TRINITRATE; INSULIN; LACTULOSE; LANSOPRAZOLE; METOPROLOL; OMEPRAZOLE; PARACETAMOL; PREDNISOLONE; PROPIOMAZINE; RABEPRAZOLE; RAMIPRIL; SALMETEROL; SPIRONOLACTONE; TOLTERODINE; TRAMADOL; UNINDEXED DRUG; WARFARIN; ZOPICLONE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL;

EID: 4043077680     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0783-7     Document Type: Article

References (21)

1. Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235-239
2. Scher ML, Huntington NH, Vitillo JA (1997) Potential interaction between tramadol and warfarin. Ann Pharmacother 31:646-647
3. Sabbe JR, Sims PJ, Sims MH (1998) Tramadol-warfarin interaction. Pharmacotherapy 18:871-873
4. Yasar U, Eliasson E, Dahl M-L, Johansson I, Ingelman-Sundberg M, Sjöqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
5. Yamada H, Dahl M-L, Lannfelt L, Viitanen M, Winblad B, Sjöqvist F (1998) CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 54:479-481
6. Chang M, Dahl M-L, Tybring G, Gotharson E, Bertilsson L (1995). Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363
7. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
8. Bertilsson L (2001) Current status: pharmacogenetics/drug metabolism. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 33-50
9. Meyer UA (2001) Pharmacogenetics: clinical viewpoints. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 135-150
10. 450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 26:289-293
11. Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11-17
12. He N, Zhang WQ, Stockley D, Edeki T (2002) Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 57:847-851
13. Yue QY, Säwe J (1997) Different effects of inhibitors on the O-and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 52:41-47
14. Gan SH, Ismail R, Wan Adnan WA, Wan Z (2002) Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. J Pharm Biomed Anal 30:189-195
15. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R et al (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42:24-29
16. 450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29:1146-1155
17. O'Reilly RA (1974) Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 16:348-354
18. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424-430
19. 450 metabolism of warfarin. Pharmacol Ther 73:67-74
20. Takahashi H, Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587-603
21. Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ et al (2000) The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 68:626-636